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Abstract Leishmania infantum is one of the important
causes of visceral leishmaniasis in many countries. There
are different complications for treatment of leishmaniasis
such as toxicity and drug resistant. So far, there isn’t any
information about the effects of selenium nanoparticles and
selenium dioxide (chemical form of selenium) on Leishman-
ia parasites; hence, the aim of the present study is to inves-
tigate in vitro effects of six dilutions of these drugs on L.
infantum. Anti-leishmanial activities were studied by adding
different dilutions of 2.5, 5, 10, 25, 50, and 100 μg/ml
of the drugs into promastigote cultures. Promastigote
cytotoxicity was tested using the colorimetric MTT assay.
Anti-amastigote activity was assessed in peritoneal macro-
phages of BALB/c mice. Also, cytotoxic effect of these drugs
was evaluated on uninfected macrophages. The results showed
that both of drugs have dose-dependent anti-leishmanial
activities. Selenium NPs have more growth-inhibitory effect
on promastigotes than SeO2; while the IC50 (50 % inhibitory
concentration) was determined to be 25 and 50 μg/ml, respec-
tively. The mean numbers of amastigotes per macrophage in
selenium NPs-treated groups were less than SeO2-treated and
control groups. The IC50 of selenium NPs was 10 μg/ml and
SeO2 was 25 μg/ml for amastigotes. Also, the IC50 of seleni-
um NPs and SeO2 for uninfected macrophages were calculated
to be 100 and 50 μg/ml, respectively. In addition, selenium
NPs has less cytotoxic effect than SeO2 on uninfected macro-
phages. These findings suggest that selenium NPs have more
anti-leishmanial properties and less cytotoxic effects than SeO2
against L. infantum.
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Introduction
Visceral leishmaniasis (VL) known as kala azar is a life-
threatening parasitic infection that may cause death in less
developed countries. Leishmania infantum is one of
the significant causes of visceral leishmaniasis in many
countries. VL is endemic in 62 countries, with a total of
200 million people at risk and estimated 500,000 new cases
each year worldwide (Guerin et al. 2002; Chappuis et al.
2007; Murray et al. 2005).
The first-line treatments for VL in many areas are penta-
valent antimonials—sodium stibogluconate and meglumine
antimoniate. Amphotericin B is also as the first-line treatment
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for VL in some areas of the Bihar State of India. Miltefo-
sine, which was initially developed as an anticancer drug,
is the first effective oral drug for VL (Chappuis et al. 2007;
Guerin et al. 2002).
There are various complications for treatment of leish-
maniasis. Antimonials have several adverse side effects such
as cardiac arrhythmia and acute pancreatitis (Chappuis et al.
2007; Guerin et al. 2002). Drug resistance in leishmaniasis
is another significant complication. There are several cases
of Leishmania being resistant to antimonials; resistance to
miltefosine and paromomycin were reported in different
countries (Maltezou 2010; Croft et al. 2006; Aït-Oudhia et
al. 2011). Therefore, searching for new drugs to overcome
these complications is needed.
Nanomedicine is defining the use of nanotechnology in
medicine, which has been of great interest in recent years.
The use of nanoparticles for therapeutics is one of the
purposes of nanomedicine (Kim et al. 2010; Irache et al.
2011). In some experimental studies, nanoparticles such as
nanogold and nanosilver have been used for treatment and
or improvement of drug delivery in leishmaniasis (Mohebali
et al. 2009; Allahverdiyev et al. 2011; Torabi et al. 2011;
Zampa et al. 2009; Durand et al. 1997a; Durand et al.
1997b; Fusai et al. 1994; Torres-Santos et al. 1999).
Selenium (Se) is a trace element with a wide range of effects
in human health, including cancer prevention, antiviral activ-
ities, and antioxidant and anti-inflammatory effects (Rayman
2012). In recent years, selenium has been fabricated in nano-
size with different methods including green method in bacteria
(Shakibaie et al. 2010). Different in vitro and in vivo studies
have been conducted on the effects of selenium NPs and other
forms of selenium (Shakibaie et al. 2010; Tran and Webster
2011; Chen et al. 2003; Huang et al. 2003; Wang et al. 2005;
Zhang et al. 2005; Wang et al. 2007; Zhang et al. 2004;
Kuppusamy et al. 2005). The main purpose for fabricating
nano-selenium is increased efficacy and decreased cytotoxicity
of selenium. As previously described, nano-selenium have less
cytotoxic effect but have equal efficacy in comparison with
other forms of selenium (Shakibaie et al. 2010;Wang et al.
2007; Zhang et al. 2005).
To our knowledge, there aren’t any reports about the
effects of selenium NPs and SeO2 (chemical form of sele-
nium) on Leishmania parasites; therefore, the aim of the
present study is to evaluate the effects of different dilu-
tions/times of these drugs on L. infantum. The second aim
of the study is to compare the cytotoxic effect of selenium
NPs and SeO2 on uninfected macrophages.
Material and methods
Selenium NPs were provided from the Department of Phar-
maceutical Biotechnology and Pharmaceutical Sciences
Research Center, Faculty of Pharmacy, Tehran University
of Medical Sciences which were synthesized by green meth-
ods from SeO2 (Shakibaie et al. 2010). SeO2 (solubility
384 g/l at 14 °C) was prepared from Merck (Darmstadt,
Germany).
Parasite culture
Promastigotes of L. infantum (WHO reference strain: MHOM/
TN/80/IPT1) were prepared from the Pasteur Institute of Iran.
For mass production, the promastigotes were cultured at 24 °C
in RPMI1640media (Gibco) supplemented with 10% fetal calf
serum (FCS) and antibiotics (100 IU/ml of penicillin and
100 μg/ml of streptomycin).
Anti-promastigote activity
Anti-promastigote assays were carried out using direct
counting assay based on growth inhibition (Yousefi et al.
2009). The effects of selenium NPs and SeO2 were evalu-
ated in 24-well microtitre plates. The promastigotes were
grown at an initial concentration equivalent to that of early
log phase (2×106 promastigotes/ml) and then allowed to
multiply for 72 h only in the RPMI medium with 10 %
FCS as control group, and in the presence of different
concentrations of selenium NPs and SeO2 (2.5, 5, 10, 25,
50, and 100 μg/ml) as test groups without renewing the
medium or drug. The promastigotes were counted at 24,
48, and 72 h in a hemocytometer with a light microscope.
Each test was performed in triplicate and repeated in sepa-
rate experiments.
Cell cytotoxicity by MTT assay
The 3-(4, 5-methylthiazol-2-yl)-2, 5-diphenyltetrazolium
bromide (MTT) test is a method that measures the ability
of cells in transforming the yellow tetrazolium crystals
(MTT) to insoluble blue formazan dye in normal cells; dead
cells are incapable of this action (Paris et al. 2004). This test
was carried out using a procedure as described earlier by
Verma and Dey (2004) and Paris et al. (2004), with some
modification. Briefly, 100 μl of promastigotes (containing
2×106 cells/ml) were added to RPMI medium as control
group or in the presence of six dilutions of selenium NPs
and SeO2 (2.5, 5, 10, 25, 50, and 100 μg/ml) at 24±1 °C
with 5 % CO2 for 72 h, then 20 μl of MTT solution was
added into each of wells and incubated again for 4-h. After
incubation, the plates were centrifuged at 6,000×g for
10 min and supernatants were aspirated gently and dis-
carded. Finally, 100 μl DMSO was added to each of wells
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to dissolve the formazan crystals and obtain a homoge-
neous blue solution suitable for measurement of the ab-
sorbance with an ELISA plate reader at 540 nm. The
amount of color produced is directly relative to the num-
ber of viable cells. Relative numbers of live cells were
determined based on the optical absorbance of the treated
and untreated samples and blank wells using the follow-
ing formula: % viable cells0(absorbance of treated cells/
absorbance of control cells)×100.
Anti-amastigote activity
Briefly, 7 ml of RPMI medium injected into peritoneum of
BALB/c mice and peritoneal macrophages were collected and
stained with trypan blue for estimation of live macrophages.
Afterward, isolated macrophages were seeded in 24-well plates
and incubated at 37 °C with 5 % CO2 for 24 h. Adhered
macrophages were infected with stationary growth phase of
promastigotes at a parasite/macrophage ratio of 10:1 and
incubated for 24 h at 37 °C and 5 % CO2 until promastigotes
were phagocyte by macrophages. Then extracellular parasites
were removed bywashedwith cold PBS. Infectedmacrophages
were separated from the plates by cold method (10–15 min on
ice) and stained by Giemsa. The percentage of infected cells
and the number of amastigotes in each cell was assessed by
light microscope. Then, infected macrophages were further
incubated in the presence of six dilutions of selenium NPs
and SeO2 (2.5, 5, 10, 25, 50, and 100 μg/ml) or absence of
these drugs for 24, 48, 72 h (37 °C with 5%CO2) without
replacing the culture medium. Finally, macrophages were
washed with PBS, fixed in methanol, stained with Giemsa
and the amastigotes inside the macrophage (200 macrophages
per treatment) were counted under a light microscope (Verma
and Dey 2004). All animals’ experimentation protocols were
approved by Animal Care and Use Committee of Medical
Sciences Faculty of Tarbiat Modares University, Tehran, Iran.
The cytotoxicity assay
For evaluation of the cytotoxic effects of selenium NPs and
SeO2 on uninfected macrophages, these cells were incubat-
ed in the presence of six dilutions (2.5, 5, 10, 25, 50, and
100 μg/ml) of both drugs at 37 °C with 5 % CO2 for 24, 48,
72 h. After 24, 48, 72 h, the percentages of live macro-
phages were calculated and compared among selenium NPs,
SeO2 and untreated control groups.
Statistical analysis
In vitro anti-leishmanial activity expressed as IC50 (50 %
inhibitory concentration), was determined by linear regression
analysis.
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Fig. 1 Growth curve of L. infantum promastigotes treated with differ-
ent dilutions of Selenium NPs (a) and SeO2 (b) after 24, 48, and 72 h
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Fig. 2 The viability of L. infantum promastigotes in the presence of
different dilutions of Selenium NPs and SeO2 assessed by MTT after
72 h
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Result
Anti-promastigote activity of selenium NPs and SeO2
For evaluation of anti-promastigote activities, six dilutions
of selenium NPs and SeO2 incubated with in vitro cultures
of L. infantum promastigotes at 24, 48 and 72 h. As shown
in Fig. 1, a dose-dependent growth inhibition was observed
at 24, 48, and 72 h after incubation; while maximum reduc-
tions of parasite proliferation were observed at 100 μg/ml of
both drugs after 72 h of incubation. The IC50 (50 % inhi-
bition concentration of cell growth) was determined to be 25
and 50 μg/ml for selenium NPs and SeO2, respectively.
Selenium NPs have more growth-inhibitory effects than
SeO2, while the percentages of viable promastigotes in
selenium NPs were less than SeO2 at all doses/times
after incubations.
Promastigotes cytotoxicity by MTT assay
Cytotoxic effects of selenium NPs and SeO2 on L. infantum
promastigotes was tested using the MTT assay after 72 h. As
shown in Fig. 2, both of the drugs have cytotoxic effects
dependent on their doses. The IC50 of selenium NPs and
SeO2 were obtained 25 and 50 μg/ml, respectively. The
viability of the promastigotes was decreased with increasing
of the doses of drugs. The maximum cytotoxic effects were
observed following exposure to 100 μg/ml concentration;
however, the cytotoxic effects of selenium NPs was more
than SeO2 at different doses.
Anti-amastigote activity of selenium NPs and SeO2
The anti-amastigote activity of selenium NPs and SeO2 were
evaluated in L. infantum-infected macrophage cultures. The
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Fig. 3 Mean number of amastigote/macrophage following exposure to
different dilutions of Selenium NPs (a) and SeO2 (b) after 24, 48, and
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Fig. 4 Percentages of viable macrophages following exposure to
different dilutions of Selenium NPs (a) and SeO2 (b) after 24, 48,
and 72 h
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mean numbers of amastigotes/macrophage was shown in
Fig. 3. The IC50 of selenium NPs was 10 μg/ml and SeO2
was 25 μg/ml for amastigotes. Selenium NPs and SeO2 have
a dose-dependent effect on amastigotes. The mean numbers
of amastigotes/macrophage in selenium NPs-treated groups
were more than SeO2-treated groups; these numbers were 2,
1.8, and 1.6 for SeO2-treated groups and were 0.4, 0.2, and 0
for selenium NPs-treated groups.
Cytotoxic effect of selenium NPs and SeO2 on macrophages
The results show that selenium NPs and SeO2 have a dose-
dependent cytotoxic effect on macrophages; while by increas-
ing drugs concentrations, the viability was decreased (Fig. 4).
Remarkably, selenium NPs have less cytotoxic effect than
SeO2 on macrophages, while the IC50 of selenium NPs was
100 μg/ml and SeO2 was 50 μg/ml. Also, the viability of
selenium NPs-treated macrophages were more than SeO2 at
all dilutions/times after treatment; for example, after 72 h
exposure to 100μg/ml of both drugs, the percentages of viable
macrophages were 70, 61, and 58 in selenium NPs-treated
group and were 61, 56, and 51 in SeO2-treated group.
Discussion
Our results revealed that both of drugs have dose-dependent
anti-leishmanial activities. In comparison of these two
drugs, selenium NPs have a more anti-leishmanial activities
and less cytotoxic effects (on uninfected peritoneal macro-
phages) than SeO2, while the IC50 of selenium NPs for
promastigote, amastigote, and macrophage was determined
25, 10 and 100 μg/ml, respectively. The IC50 of SeO2 was
calculated to be 50, 10, and 50 for promastigote, amastigote,
and macrophage respectively. We observed selenium NPs
have less cytotoxic effect on uninfected macrophages but
have more anti-amastigote and anti-promastigote activities
than SeO2.
There are some evidences that other nanoparticles such as
nanosilver and nanogold have anti-leishmanial activities on
Leishmania major and Leishmania tropica (Mohebali et al.
2009; Allahverdiyev et al. 2011; Torabi et al. 2011). Also
Zampa et al. (2009) observed that the nanostructure form of
dermaseptin 01(antimicrobial peptides) has in vitro anti-
leishmanial activities on Leishmania chagasi. In addition,
the use of nanoparticles for improving drug delivery was
evaluated in the mouse model of visceral leishmaniasis by
some workers. They showed that pentamidine bounded with
nanoparticles are more potent than the free drugs for treat-
ment of L. infantum-infected mice (Durand et al. 1997a, b;
Fusai et al. 1994).
Previous studies revealed that selenium at nano-size can
serve as antioxidant (Huang et al. 2003; Wang et al. 2007)
with lower toxic effects than selenium (Wang et al. 2007;
Zhang et al. 2005; Shakibaie et al. 2010). In this regard,
Shakibaie et al. (2010) observed green synthesis of nano-
selenium have lower toxicity than other forms of selenium
in human fibrosarcoma cells. Wang et al. (2007) showed that
selenium at nano-size have lower toxicity than selenome-
thionine but possesses equal efficacy in activities of gluta-
thione peroxidase and thioredoxin reductase compared with
selenomethionine. Also, Zhang et al. (2005) compared tox-
icity of nano-selenium and selenite in mice. They showed,
over a short term and high dose treatment in mice, that
selenite could cause more oxidative stress and liver injury
than nano-selenium.
According to GuanYi et al. (2010), nano-selenium could
induce apoptosis in HeLa cell line (GuanYi et al. 2010).
Moreover, SeO2 could induce apoptosis and inhibiting the
telomerase activity in lung cancer cells (Chen et al. 2003).
Also melatonin selenium nanoparticles could inhibit oxida-
tive stress induced by lipopolysaccharide in mice (Wang et
al. 2005). Tran and Webster (2011) also observed in vitro
proliferation of Staphylococcus aureus inhibition by seleni-
um nanoparticles. Other studies revealed that SeO2 could
inhibit in vitro proliferation of breast and lung cancer cells
(Kuppusamy et al. 2005; Chen et al. 2003).
In conclusion, the results of our study revealed that seleni-
um NPs and SeO2 have dose-dependent anti-leishmanial ac-
tivities. Also, selenium NPs have more anti-leishmanial
activities with less cytotoxic effects than SeO2.
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